Which of the following newly approved drugs is used in the treatment of Parkinson’s disease?
A. Mirabegron
B. Rotigotine
C. Trametinib
D. Pasireotide
E. Olodaterol
Answer: B
Rotigotine is a transdermal dopamine agonist for Parkinson's disease and restless legs syndrome.
Mirabegron- A beta-3 agonist for overactive bladder; Trametinib- A kinase inhibitor for advanced melanoma; Pasireotide - A somatostatin analogue for Cushing's disease; Olodaterol- Inhaled long-acting beta-agonist bronchodilator for COPD.
Which of the following fentanyl formulations is not approved in Canada?
A. IV Solution
B. Transdermal Patch
C. Sublingual Tablet
D. Nasal Spray
E. None of the above
Answer: E
C-Fentora and D-Instanyl have been approved in 2013.
A list of new drug dosage forms approved by Health Canada in 2013 is available at www.cpepreponline.com under “Free Pharmacy Resources #1”
Integrase inhibitors also called integrase strand transfer inhibitors belong to the class of antiretroviral drugs used in the treatment of HIV infection. They inhibit the action of the viral enzyme integrase that inserts the viral genome into the DNA of the host cell. Integrase inhibitors are co-administered with other antiretroviral agents. Which of the following drugs are integrase inhibitors?
I. Raltegravir
II. Dolutegravir
III. Elvitegravir
A. I only
B. III only
C. I and II only
D. II and III only
E. I, II, and III
Answer: E
Dolutegravir and Elvitegravir have been approved in 2013.
